MCI-186
MCI-186-J22
Phase 1 small_molecule completed
Quick answer
MCI-186 for Renal Impairment is a Phase 1 program (small_molecule) at Tanabe Pharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tanabe Pharma
- Indication
- Renal Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed